Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Oct 1;14(5):883-888.
doi: 10.21037/hbsn-2025-404. Epub 2025 Sep 26.

Reconciling diagnostic definitions for proposing metabolic dysfunction-associated steatotic liver disease in chronic kidney disease risk

Tsubasa Tsutsumi  1   2 , Takumi Kawaguchi  2 , Hiroyuki Suzuki  2   3 , Ryuki Hashida  4 , Shuhei Fukunaga  2 , Masahito Nakano  2 , Mary E Rinella  1
Affiliations
Editorial

Reconciling diagnostic definitions for proposing metabolic dysfunction-associated steatotic liver disease in chronic kidney disease risk

Tsubasa Tsutsumi et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Chronic kidney disease (CKD); consensus definition; diagnostic criteria; metabolic dysfunction-associated steatotic liver disease (MASLD); non-alcoholic fatty liver disease (NAFLD).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-404/coif). T.T. reports consulting fees from Madrigal. T.K. reports honoraria from ASKA Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., AbbVie GK., Eisai Co., Ltd., EA Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Otsuka Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K. M.E.R. reports consulting fees from Akero, 89Bio, Boehringer Ingelheim, Intercept Pharmaceuticals, Histoindex, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, Eli Lilly, Sagimet Biosciences, Sonic Incytes, Cytodyn, and GSK; leadership or fiduciary role with Akero, Madrigal, Eli Lilly and Novo Nordisk. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Multiorgan distribution of similar disease prevalence and clinical incidence between patients with NAFLD and MASLD (13-21). CLDQ-NAFLD values and SWE (kPa) values are presented as median (interquartile range). ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CLDQ-NAFLD, chronic liver disease questionnaire-NAFLD; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; HCC, hepatocellular carcinoma; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease; QOL, quality of life; SWE, shear wave elastography.
See this image and copyright information in PMC

Comment on

References

    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-56. 10.1016/j.jhep.2023.06.003 - DOI - PubMed
    1. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res 2024;65:100485. 10.1016/j.jlr.2023.100485 - DOI - PMC - PubMed
    1. Heo JH, Lee MY, Kim SH, et al. Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: a cohort study. Hepatobiliary Surg Nutr 2024;13:801-13. 10.21037/hbsn-23-558 - DOI - PMC - PubMed
    1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9. 10.1016/j.jhep.2020.03.039 - DOI - PubMed
    1. Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. Metabolism 2021;115:154433. 10.1016/j.metabol.2020.154433 - DOI - PubMed

LinkOut - more resources